Transgene SA (TRGNF)

1.6200 0.0000 (0.00%) At close: 01:14PM EDT

Transgene SA

400, boulevard Gonthier d’Andernach
Parc d’innovation CS80166 Cedex
Illkirch-Graffenstaden 67405
France
33 3 88 27 91 00
https://www.transgene.fr

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Alessandro Riva M.D.	CEO & Chairman of the Board	71.38k	N/A	1961
Ms. Lucie Larguier	Chief Financial Officer	N/A	N/A	N/A
Dr. Eric Quemeneur Ph.D., Pharm.D.	Executive VP & Chief Scientific Officer	N/A	N/A	1965
Mr. John Felitti J.D., LLM	VP, General Counsel & Corporate Secretary	N/A	N/A	1970
Ms. Christelle Schwoerer	Chief Human Resources Officer	N/A	N/A	N/A
Dr. Maud Brandely-Talbot M.D., Ph.D.	VP of Medical Affairs & Chief Medical Officer	N/A	N/A	1954
Mr. James Wentworth M.B.A., Ph.D.	VP & Chief Business Officer	N/A	N/A	N/A
Ms. Gaelle Stadtler	VP & Director of Human Resources	N/A	N/A	1984
Kaidre Bendjama	Project Leader of Personalized Cancer Vaccines	N/A	N/A	N/A
Ms. Elisabetta Castelli Ph.D.	Director of Investor Relations	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Corporate governance

Transgene SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.